General
Preferred name
APREMILAST
Synonyms
CC-10004 ()
Apremilast (CC 10004) ()
Apremilast (CC-10004) ()
Apremilast-d5 ()
Otezla ()
CC10004 ()
Apremilast accord ()
P&D ID
PD009329
CAS
608141-41-9
1258597-47-5
Tags
available
drug
Approved by
EMA
PMDA
FDA
First approval
2014
Drug indication
atopic eczema
Psoriasis vulgaris
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY DEPRESSION AND SUICIDE: Apremilast has been associated with increased depression and suicidal behaviour in patients. ; WEIGHT LOSS: Apremilast has been associated with weight decrease in patients.
DESCRIPTION Apremilast is an oral small molecule phosphodiesterase 4 (PDE4) inhibitor (additional comment in ). It is selective for PDE4 over other PDE isozymes, but non-selective over PDE4 isoforms . (GtoPdb)
DESCRIPTION Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-¦Á release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1].
PRICE 55
DESCRIPTION Apremilast is a non-steroidal medication used for the treatment of inflammatory conditions such as psoriasis and psoriatic arthritis. It is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. (Enamine Bioactive Compounds)
DESCRIPTION Apremilast (CC-10004) (CC-10004) is a potent and orally active PDE4 (IC50=74 nM) with anti-inflammation activities. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
0
Compound Sets
25
AdooQ Bioactive Compound Library
A11289
Axon Medchem Screening Library
1957
Cayman Chemical Bioactives
18502
22553
ChEMBL Approved Drugs
CHEMBL514800
ChEMBL Drugs
CHEMBL514800
Concise Guide to Pharmacology 2017/18
7372
Concise Guide to Pharmacology 2019/20
7372
Concise Guide to Pharmacology 2021/22
7372
Concise Guide to Pharmacology 2023/24
7372
Drug Repurposing Hub
DrugBank
DB05676
DrugBank Approved Drugs
DB05676
DrugCentral
4829
DrugCentral Approved Drugs
4829
DrugMAP
DMTWS9E
DrugMAP Approved Drugs
DMTWS9E
Enamine Bioactive Compounds
EBC-27155
EU-OPENSCREEN Bioactive Compound Library
EOS101244
Guide to Pharmacology
7372
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL514800
MedChem Express Bioactive Compound Library
HY-12085
NCATS Inxight Approved Drugs
UP7QBP99PN
ReFrame library
Selleckchem Bioactive Compound Library
apremilast-cc-10004
TargetMol Bioactive Compound Library
T2923
External IDs
46
Properties
(calculated by RDKit )
Molecular Weight
460.13
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
2
cLogP
2.43
TPSA
119.08
Fraction CSP3
0.32
Chiral centers
1.0
Largest ring
6.0
QED
0.6
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Apoptosis
Phosphodiesterase (PDE)
TNF Receptor
PDE4
phosphodiesterase
PDE4A, PDE4B, PDE4C, PDE4D
PDE4 inhibitor
PDE,TNF-alpha
Indication
psoriasis, psoriatic arthritis
Disease Area
dermatology, rheumatology
MOA
phosphodiesterase inhibitor
Pathway
Metabolism
Metabolic Enzyme/Protease
Source data